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Abstract
Background and Objectives Generic substitution has
been introduced in most countries in order to reduce costs
and improve access to drugs. However, regulations and the
generic drugs available vary between countries. It is the
prescriber or dispenser of the drug who is the final decision
maker. Nevertheless, physicians’ and pharmacists’ per-
ceptions of generic drug use are not well documented to
date. This study presents a systematic review of physicians’
and pharmacists’ perspectives on generic drug use
worldwide.
Methods A systematic literature search was performed to
retrieve all articles published between 2002 and 2012
regarding physicians’ and/or pharmacists’ experiences with
generic drugs and generic substitution.
Results Of 1322 publications initially identified, 24 were
eligible for inclusion. Overall, the studies revealed that
physicians and pharmacists were aware of the cost-saving
function of generic drugs and their role in improving global
access to drugs. Nevertheless, marked differences were
observed between countries when studying physicians’ and
pharmacists’ perceptions of the available generic drugs. In
less mature healthcare systems, large variations regarding,
for example, control routines, bioequivalence require-
ments, and manufacturer standards were reported. A lack
of reliable information and mistrust in the efficacy and
quality were also mentioned by these participants. In the
most developed healthcare systems, the participants trusted
the quality of the generic drugs and did not hesitate to offer
them to all patients regardless of socioeconomic status. In
general, pharmacists seemed to have better knowledge of
the concept of bioequivalence and generic drug aspects
than physicians.
Conclusions The present study indicates that physicians
and pharmacists are aware of the role of generic drugs in
the improvement of global access to drugs. However, there
are marked differences regarding how these health pro-
fessionals view the quality of generic drugs depending on
the maturity of their country’s healthcare system. This can
be attributed to the fact that developed healthcare systems
have more reliable public control routines for drugs in
general as well as better bioequivalence requirements
concerning generics in particular.
Key Points for Decision Makers
Generic drugs are generally seen as an important
instrument for achieving better equity and access to
drugs.
In mature healthcare systems, both pharmacists and
physicians support the use of generic drugs and offer
them to all patients regardless of socioeconomic
status.
A lack of trust in manufacturers and the quality of
the generic drugs affect how pharmacists and
physicians consider generic drug use in less mature
healthcare systems.
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1 Introduction
In order to reduce the growth in national healthcare
spending, generic drugs are being increasingly used in most
countries worldwide [1, 2]. Treatment of many patients, and
in particular of those in developing countries, is now pos-
sible because of low-cost generic drugs [3]. However, drug
control routines vary between countries, as do the number
of drugs available. A brand name or reference drug can
only be substituted by a generic drug when the latter con-
tains the same active ingredient and strength as the refer-
ence drug, and is administered in the same dosage form. The
difference in bioavailability between the two drugs should
ideally lie within the therapeutic bioequivalence interval
(the 90 % confidence interval of the ratio of a log-trans-
formed test to reference mean area under the curve (AUC),
which shows drug absorption, and maximum plasma level
during drug absorption (Cmax) values falling within the
range of 80–125 %) [4]. However, these regulations are not
enforced by all governments. Further, the existence of
several generic alternatives to a branded product leads to
challenges for patients and healthcare personnel [5–7]. The
switch from a brand name to a generic drug may prove more
of a challenge for certain patient groups than others. For
example, elderly patients and polypharmacy users can
easily become confused, especially since the new product
can differ in shape, taste, and colour [5, 7].
As early as 1968, the UK introduced compulsory generic
prescribing as part of their national health system [8]. In
the following decade, the first publications regarding
experiences with generic substitution appeared in the USA
[9, 10]. Since generic prescribing does not involve a switch
from a specific brand prescribed by the physician to a
product perceived as ‘‘cheaper’’ by the patient, it has been
argued that generic prescribing might cause less confusion
compared with generic substitution [11].
In 2012, Ha˚konsen and Toverud [2] published a review
on patient perspectives on generic substitution. This review
was exclusively based on studies from the developed world
given the perceived limitations on the applicability of
generic substitution in developing countries. Explanatory
factors were high illiteracy rates, low educational levels,
and limited access to healthcare, as well as large differ-
ences between rural and urban areas. It has been further
suggested that patients in countries with mature healthcare
systems are, in general, treated with medically adequate
generic drugs [11]. Nevertheless, the challenges mentioned
above can lead to reduced drug adherence or double dos-
ing, and the issue of confusion can become even more
severe if patients are treated by several physicians and
attend different pharmacies [2]. Additionally, physicians
and pharmacists respectively prescribing and dispensing
drugs also face important challenges in relation to generic
drug use. Exploring their perspectives and perceptions may
thus increase the understanding of said challenges. Fur-
thermore, by focusing on healthcare professionals with
knowledge of their healthcare systems, it should be possi-
ble to obtain a broader international perspective of these
challenges. Therefore, the aim of the present study was to
systematically review physicians’ and pharmacists’ per-
spectives on generic drug use based on the available pub-
lications worldwide.
2 Methods
A systematic literature search in MEDLINE (PubMed) and
SciVerse Scirus (discontinued in 2014) was performed
between July and December 2012 for peer-reviewed, ori-
ginal research articles regarding physicians’ and pharma-
cists’ experiences with and attitudes towards generic drugs
and generic drug prescribing/substitution. The following
terms were employed in the search strategy, using Boolean
operators to refine the search (where possible, MeSH terms
were applied): ‘‘generic drug’’, ‘‘generic substitution’’,
‘‘generic prescribing’’, or ‘‘INN prescribing’’ combined
with either ‘‘healthcare provider’’ and/or ‘‘healthcare pro-
fessional’’ and/or ‘‘physician’’ and/or ‘‘pharmacist’’.
Articles published in English from 2002 onwards were
included. This publication time frame was chosen given
that the process of generic substitution was generally
established within this period in most countries. Publica-
tions based on prescription data were excluded. Figure 1
shows the initial number of identified articles, the assess-
ment of eligible articles (according to the exclusion cri-
teria), and the final number of included articles. Overall, 24
articles assessing physicians’ (n = 16) and pharmacists’
(n = 8) experiences and attitudes were included in the
review. It is noteworthy that the previous review by
Ha˚konsen and Toverud [2] on patients’ perspectives
included a similar number of articles. Tables 1 and 2
provide an overview of the articles included, listed
according to authorship and year of publication, country




Paraponaris et al. [12] conducted a study assessing the
attitudes of 600 French general practitioners (GPs)
regarding generic prescribing (Table 1) and found that
76 % of the respondents confirmed their willingness to do
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so. Gender, age, billing sector, length of practice, or
additional degrees were not associated with this intention,
nor were the socioeconomic background or unemployment
rate of the local population. However, meeting with more
than ten pharmaceutical sales representatives per week was
a factor associated with reluctance for generic prescribing.
Another study of GP’s attitudes towards generic pre-
scribing was carried out by Kersnik and Peklar [13] in
Slovenia. This study included 200 GPs, representing 15 %
of Slovenia’s GPs, who received a postal survey ques-
tionnaire and a prepaid return envelope. The majority of
GPs responded that they usually met their patients’
demands or hospital consultant requests for branded
products. Overall, 38 % did not consider the price when
prescribing drugs, and 16 % felt that the pharmaceutical
industry had a tremendous impact on their prescribing.
Further, 90 % perceived generics to be as effective as
branded drugs. Nevertheless, 25 % stated that they would
only increase generic prescribing if additional clinical trials
were presented.
De Run and Felix [14] initially interviewed 15 physi-
cians from various public hospitals in one of Malaysia’s
provinces using a semi-structured questionnaire. The
insights obtained were used to develop a questionnaire
answered by a further 62 physicians. The study explored
physicians’ perceptions towards patented and generic drugs
as well as factors influencing their prescribing decisions.
The respondents viewed patented medicines as superior in
quality, efficacy, and safety. Further, generic medicines
were perceived as more affordable for the majority of the
population, but lacking quality control and of uncertain
efficacy. The physicians reported that the factors mostly
affecting their prescribing decisions included their own
experiences, evidence from the literature, their patients’
ability to afford the medication, and hospital policy.
In Hassali et al.’s [15] study performed in Melbourne,
Australia, ten GPs were interviewed using a semi-struc-
tured questionnaire. The respondents had mixed attitudes
towards generic prescribing—some viewed generics as
equally effective as the innovator brand, but, when
asked, no GP was aware of the acceptability criteria for
bioequivalence of generic drugs. Further, they mentioned
that they were concerned about patient confusion following
substitution, and some felt that their role as a prescriber
was threatened when pharmacists dispensed the generic
drug.
Using the local telephone directory in Jamaica, Gossell-
Williams [16] included and examined the attitudes of 100
physicians of various specialities (mostly GPs in private
practices) towards generic substitution. Overall, 60 ques-
tionnaires were returned completed, 49 % of the physicians
claimed that they prescribed generic drugs when cost was a
significant factor for the patient, 29 % answered that they
prescribed approximately equal numbers of the two drug
categories, and 22 % said that they usually prescribed
brand name drugs. Approximately half of the respondents
felt that bioequivalent generics were therapeutically
equivalent to branded drugs; 33 % stated that they could
identify at least one case of clinical problems related to
generic substitution over the previous year and mentioned
that this would not have occurred with brand name drugs.
The author concluded that more emphasis should be placed
on improving physician confidence in the therapeutic
equivalence of generics.
In Finland, Heikkila¨ et al. [17] explored how physicians
(and customers) viewed the reform when generic sub-
stitution was introduced in 2003. The reform specifies that
pharmacists are obliged to dispense the cheapest possible
generic product as a substitute to prescribed medicines
unless the physician has excluded substitution, which is
only possible for medical reasons. In this study, 49 phy-
sicians (psychiatrists, geriatrists, internists, and GPs) were
interviewed personally, and most believed that generic
Literature search in databases
Screening by tle and abstract
n = 1322
Final inclusion of arcles
Physicians: n = 16
Pharmacists: n = 8 
n = 1283 excluded due to:
Non-original research
Published prior to 2002
Wrien in language other than 
English
Healthcare provider/professional 
not being physician or pharmacist
Full text reading
n = 39
n = 15 excluded due to:
Non-matching study aims 
Studies dealing with drug therapies 
with narrow therapeuc windows
Fig. 1 Flow chart of articles identified, screened, assessed for
eligibility, and included in the review
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substitution was a good reform, mainly with regards to cost
reduction. However, approximately half thought that not all
interchangeable medicines were effective and safe.
Polinski et al. [18] assessed GPs’ opinions of generic
substitution (introduced in 1994) and the Reference Drug
Program (RDP) for the elderly (from 1995) in British
Columbia, Canada. Of the 1050 GPs who were contacted,
210 agreed to be interviewed by telephone. Overall, the
GPs rated the economic appropriateness of both generic
substitution (87 %) and RDP (74 %) positively. However,
they were less enthusiastic regarding the clinical appro-
priateness (70 % regarding generic substitution and 50 %
regarding RDP). The most common concerns were whether
drug switching and reduced adherence led to poorer health
outcomes and whether the RDP could correctly identify
therapeutically equivalent drugs.
Alghasham’s study [19] from Saudi Arabia assessed
physicians’ perceptions and attitudes towards generic pre-
scribing by sending a self-administered questionnaire to a
random sample of 900 physicians from primary healthcare,
hospitals, or private practice. The majority of the physi-
cians (96 %) reported that they had adequate knowledge of
the therapeutic value of the generic drugs they prescribed.
Primary care physicians were significantly more likely to
prescribe generically than hospital and private physicians
(47, 31, and 22 %, respectively). However, only 16 %
Table 1 Articles regarding physicians’ perspectives included in the literature review (n = 16) in chronological order
References Country Method Number of participants
Paraponaris et al. (2004) [12] France Postal survey, databases 600 (RR 55.8 %)
Kersnik and Peklar (2006) [13] Slovenia Postal survey 117 (RR 58.5 %)
De Run and Felix (2006) [14] Malaysia Personal interviews (semi-structured), postal survey 15 (a)
62 (a)
Hassali et al. (2006) [15] Australia Personal interviews (semi-structured) 10 (a)
Gossell-Williams (2007) [16] Jamaica E-postal/telephone/personal survey 60 (RR 60.0 %)
Heikkila¨ et al. (2007) [17] Finland Personal interviews (structured) 49 (a)
Polinski et al. (2008) [18] Canada Telephone survey 210 (RR 20.0 %)
Alghasham (2009) [19] Saudi Arabia Postal survey 772 (RR 85.8 %)
Tsiantou et al. (2009) [20] Greece Postal survey 1204 (RR 82.3 %)
Theodorou et al. (2009) [21] Greece
Cyprus
Postal survey 1204 (RR 82.3 %)
193 (RR 80.4 %)
Chua et al. (2010) [22] Malaysia Postal survey 87 (RR 26.8 %)
Shrank et al. (2011) [23] USA Web-based survey 506 (RR 18.3 %)
Jamshed et al. (2011) [24] Pakistan Personal interviews (semi-structured) 11 (a)
Jamshed et al. (2012) [25] Pakistan Self-administered questionnaires 289 (RR 71.3 %)
Fabiano et al. (2012) [26] Italy Web-based survey 303 (a)
Skinstad (2012) [27] Norway Telephone survey 91 (a)
RR response rate
a Response rate not applicable/unavailable
Table 2 Articles regarding pharmacists’ perspectives included in the literature review (n = 8) in chronological order
References Country Method Number of participants
Allenet and Barry (2003) [28] France Postal survey 1000 (a)
Babar and Awaisu (2008) [29] Malaysia Postal survey 40 (a)
Gill et al. (2010) [30] Australia, Finland, Italy Personal interviews 45 (a)
Chong et al. (2011) [31] Australia Postal survey 500 (RR 16.4 %)
Babar et al. (2011) [32] New Zealand Postal survey 625 (RR 58.0 %)
Chong et al. (2011) [33] Malaysia Postal survey 219 (RR 15.4 %)
Olsson and Ka¨lvemark Sporrong (2012) [34] Sweden Semi-structured interviews 16 (a)
Basak and Sathyanarayana (2012) [35] India Personal interviews (structured) 66 (a)
RR response rate
a Response rate not applicable/unavailable
S38 E.-L. Toverud et al.
supported using generics (if available) in ‘‘all’’ clinical
situations, whereas the majority supported generics in
‘‘most’’ cases. Further, 85 % were positive towards the
government’s role in enforcing physicians to prescribe
generic drugs. The physicians reported that representatives
from generic drug companies were less likely to visit them
than representatives from brand drug companies, and that
they received significantly more drug samples from the
brand name drug companies. An equal percentage of
physicians ‘‘sometimes’’ felt pressured by patients to pre-
scribe either brand drugs (41 %) or generic drugs (40 %).
Greek physicians’ perceptions and prescribing practices
were studied by Tsiantou et al. [20] using a structured
questionnaire with 25 semi-closed questions sent by mail to
a random sample of 1463 physicians, stratified by gender,
speciality, and geographical region. Overall, 75 % of
physicians claimed that they were not affected by the sales
representatives from drug companies and that Greek
patients do not interfere with their prescribing, but often
complain about the drug cost. When asked about quality,
half of the respondents characterized the quality of generics
as high or very high and claimed that implementation of an
International Nonproprietary Name system was necessary.
However, only 25 % prescribed generics.
Based on the study by Tsiantou et al. [20], Theodorou
et al. [21] performed a comparison between Greek and
Cypriot physicians. The previously developed postal
questionnaire was sent to 240 physicians in Cyprus to add
to the previously surveyed 1463 Greek physicians. Overall,
50 % of the Greek physicians and 60 % of those in Cyprus
felt that the quality, safety, and effectiveness of generic
drugs was ‘‘high’’ or ‘‘very high’’. However, only 25 % of
the Greek physicians said that they often prescribed a
generic product instead of a branded one compared with
66 % of physicians in Cyprus. When the physicians in the
two countries were questioned regarding their motivation
to prescribe a generic drug, approximately 60 % indicated
the patient’s out-of-pocket expenses for the drug were
‘‘important’’ or ‘‘highly important’’.
Chua et al. [22] evaluated GPs’ knowledge and per-
ceptions of generic medicines in Malaysia using a 23-item
questionnaire sent by post to registered GPs. The majority
of GPs (85 %) claimed that they actively prescribed
generic drugs, but only 5 % correctly identified Malaysia’s
National Pharmaceutical Control Bureau’s bioequivalence
standard for generic products; there were misconceptions
about the meaning of ‘‘bioequivalence’’, ‘‘efficacy’’,
‘‘safety’’, and ‘‘manufacturing quality standards’’. It
appeared that, although the Malaysian GPs were largely
prescribing generics, they still had concerns regarding the
reliability and quality of such products. The GPs believed
that a standard guideline on generic substitution, collabora-
tion with pharmacists, patient education, and information
on the safety and efficacy of generic medicines were
necessary to ensure quality in the use of generics. The study
revealed that the choice of drug depended on advertising and
product incentives/bonuses offered by pharmaceutical
companies, the patient’s socioeconomic background, and
the credibility of manufacturers.
Shrank et al. [23] invited 2764 physicians from the
USA to formulate their perceptions of generic medicines.
Of the 839 doctors who completed the survey, 506 were
found eligible and were included in the final study popu-
lation. Of these, over 23 % were negative towards the
efficacy of generic drugs and almost 50 % reported nega-
tive perceptions with regards to quality. Physicians older
than 55 years of age were more than three times as nega-
tive to generics as younger doctors. The youngest physi-
cians (under the age of 35) were significantly less likely to
hold negative views regarding the quality and more likely
to report a personal preference for generics or to recom-
mend them to their family. Pharmaceutical companies were
reported as the most common source of information about
generic drugs (75 %).
Jamshed et al. [24] published a study including 11
physicians in Pakistan, where 80 % of the doctors both
prescribe and dispense drugs, and bioequivalence studies
are not required for generic substitution. The respondents
were identified by snowballing, and the interviews were
carried out using a semi-structured interview guide. It was
revealed that the knowledge of dispensing doctors about
generic medicines was sparse; for example, they confused
the expression of generic substitution with generic pre-
scribing. Further, mixed views and attitudes were identified
towards generic medicines and the term bioequivalence
was not understood. Some physicians considered generic
medicines to be as safe and effective as any branded pro-
duct when they were produced by high-quality national
companies. The doctors admitted to being influenced by the
pharmaceutical companies to preferentially prescribe their
products; the acceptance of international trips to confer-
ences and compensatory gifts (even cars) was admitted.
In a further study, Jamshed et al. [25] interviewed 289
randomly selected GPs with a questionnaire regarding their
perceptions of and attitudes towards generic drugs. Close to
75 % of the respondents answered ‘‘correctly’’ regarding
generics since they knew them to be ‘‘a copy of the brand
name medicine’’ and/or ‘‘interchangeable with brand name
medicines’’. Overall, 55 % thought that generic medicines
are therapeutically equivalent to branded drugs, whereas
59 % said that generics are less safe, and 58 % were of the
opinion that only local reputable manufacturers produce
safe generic medicines. Concerning brand name products,
physicians stated that they were of better quality than
generics (59 %), that they were required to meet higher
safety standards (77 %), and that they had fewer side
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effects (66 %). The authors concluded that gaps in
knowledge of generic medicines had been identified among
their participants.
In Italy, Fabiano et al. [26] conducted a nationwide web-
based survey aiming to evaluate the knowledge of generic
medicines and prescribing habits of family paediatricians.
The hypothesis was that Italian GPs and family paedia-
tricians were less confident in prescribing generics than
physicians elsewhere and, therefore, that generic drug
prescribing would be low. In total, 303 family practitioners
filled out the online questionnaire. The majority believed
that the efficacy of generic medicines was sufficient (34 %)
or good (45 %), and 37 and 33 % of them declared
themselves to have a sufficient or fairly good knowledge of
generic medicines, respectively. However, only 14 % sta-
ted that as much as half of their patients were treated with
generics. The major issues preventing generic prescribing
were identified to be the widespread scepticism about the
reliability of bioequivalence tests and the safety of
switching from branded to generic equivalents. The authors
concluded that more information regarding generic drugs
and further research in the field of paediatric pharmacology
were required to increase generic drug prescribing among
Italian family paediatricians.
Using a structured questionnaire, Skinstad [27] per-
formed telephone interviews with 91 GPs from all counties
in Norway regarding their attitudes and experiences with
generic substitution. In Norway, it is obligatory for the
pharmacist to perform generic substitution if the physician
has not actively excluded substitution for medical reasons
on the prescription, unless the patient denies substitution
and pays the price difference between the generic and the
brand product. Overall, 75 % of doctors were positive
toward the system despite complaining that it was time
consuming. They also feared impaired health outcomes
since they were worried about poor drug adherence caused
by confusion and anxiety. Only half of the doctors reported
that they prescribed generics to some or a high degree. A
key reason for brand name prescribing was their memory
of the brand name and the confidence that the pharmacist
would take care of the substitution.
3.2 Pharmacists
Allenet and Berry [28] assessed the opinions and behaviour
of community pharmacists in France towards generic
substitution (Table 2). Since 1999, the pharmacists have
had the right to switch from branded to generic medicines
unless the prescriber has specified otherwise. A structured
questionnaire was sent by mail to be filled out by the
pharmacy owner. Most respondents (91 %) agreed that the
pharmacists’ right to substitute is ‘‘a good thing’’. Less than
half of the study population (43 %) reported that they
systematically offered the patient a generic drug, whereas
55 % claimed to target specific populations for substitu-
tion. Overall, 80 % felt that the substitution system
improved pharmacists’ influence within the healthcare
system, but at the same time, 70 % stated that substitution
was difficult to implement. Only 51 % considered the fi-
nancial compensation for the sale of generic drugs to be
satisfactory, and 85 % stated that training was necessary.
Nevertheless, the majority (86 %) had positive attitudes
towards generic prescribing.
Babar and Awaisu [29] evaluated community pharma-
cists’ perceptions and practices on generic drugs in the
Malaysian peninsula. Of the pharmacists surveyed, 47 %
recommended original brands over generics, whereas the
opposite was stated by another 47 %. Further, 45 % had
‘‘high’’ or ‘‘very high’’ confidence in the Malaysian generic
approval system regarding bioequivalence, and as much as
93 % of the respondents were confident that the generic
drugs they dispensed had been subjected to bioequivalence
control before approval. The participants said that they
always considered affordability for customers first, and
85 % felt that the customer usually accepted their recom-
mendation for generic drugs. However, 62 % said that
compulsory generic substitution should not be imple-
mented in Malaysia since the situation with generic drugs
remained unclear.
Gill et al. [30] studied how pharmacists (and customers)
experienced generic substitution in Finland as compared
with Australia and Italy by interviewing 15 pharmacists
from each country. In Finland, where generic substitution
is generally accepted, the pharmacists were concerned
about customer confusion following substitution. A phar-
macist stated: ‘‘don’t talk about substitution to old custo-
mers who have many challenges already, or those who
have dementia’’, whereas another stated: ‘‘I have to offer
the generics even if the customer is not listening.’’ The
Australian pharmacists reported that it took time to instruct
‘‘resistant customers’’, especially polypharmacy users,
patients with mental illness, and those with dementia. The
Italian and Australian pharmacists experienced frustration
when the customer did not believe that the generic was
equivalent to the branded medicine. The respondents also
reported that physicians act as a significant barrier; the
Australian pharmacists, for instance, remarked that 50 %
of the patients requested discussion with their doctor before
they would accept generic substitution. In general, phar-
macists in all three countries felt that it was a professional
challenge to educate customers about the generic substi-
tution system.
Chong et al. [31] evaluated the Australian community
pharmacists’ rate of generic substitution, patient accep-
tance of the substitution, and the cost saving achieved for
patients. A national stratified sample of 500 pharmacies
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was randomly selected, and the first 25 original prescrip-
tion items that were eligible for generic substitution dis-
pensed during 1 working day were collected from each
pharmacy. It was found that the pharmacists recommended
generics for 96 % of the items that were eligible for sub-
stitution. Further, the recommendation rate was significantly
higher in urban areas compared with remote areas, whereas
the opposite was found for patient acceptance. A signifi-
cant difference between patient acceptance for chronic
diseases (72 %) and acute conditions (82 %) was also noted.
Through acceptance of substitution, the patients’ medicine
expenditure was reduced by approximately 21 %. Finally,
the authors concluded that patient acceptance required
further improvement.
Babar et al. [32] surveyed pharmacists’ (n = 625)
views, knowledge, and perception of generic medicines in
New Zealand. Only 30 % of pharmacists correctly identi-
fied the properties of generic medicines (namely safety,
effectiveness, quality, and cost). Those who had been in
practice less than 5 years had a better understanding of the
substitution system than those who had been in practice for
5 years or more. As much as 65 % believed that original
brand products were of better quality, and 70 % perceived
no difference in safety between original brands and
generics. However, 16 % were against generics produced
in emerging markets. The pharmacists’ perception was
reported to be affected by consumer preferences or demand
(76 %), professional judgment (72 %), and the manufac-
turer’s reputation (45 %). Furthermore, 56 % thought that
generic medicines had no impact on adherence and 76 %
stated that generic medicines are cost effective for the New
Zealand healthcare system. Nevertheless, only 3 % sup-
ported more frequent prescribing of generic medicines and
84 % were worried about a ‘‘reduced profit’’ when dis-
pensing generic drugs.
Chong et al. [33] evaluated community pharmacists’
views on generic drugs in Malaysia. Half of the pharma-
cists agreed that all products approved to be bioequivalent
could be considered therapeutically equivalent to the ref-
erence drug (brand name drug), and 76 % indicated that
generic substitution of drugs with narrow therapeutic
windows was inappropriate. The majority of the pharma-
cists (85 %) stated that a generic medicine must contain the
same amount of the active ingredient as the original brand,
and 72 % stated that it must be in the same dosage form.
Approximately 21 % thought that generic medicines, in
general, were of inferior quality compared with the origi-
nal, and a minority also thought that generic drugs had
more side effects. They further reported that customers
showed a high degree of mistrust when the manufacturer
was unknown and deemed it difficult to explain that a drug
with a different shape and colour can have the same effi-
cacy as the drug previously used.
Olsson and Ka¨lvemark Sporrong [34] interviewed 16
Swedish pharmacists using a semi-structured interview
guide and found that most pharmacists were in favour of
generic substitution because of the economic benefits.
However, they felt that they lacked education regarding
both the substitution system and generic drugs in general.
Most considered generics to be equivalent with and as
effective as the original product. In contrast to these
statements, some pharmacists were confused since many
patients reported a lack of effect as well as new side
effects. The pharmacists felt that a reason for the mistrust
could be that generics could have different tablet coating,
lack calendar packaging, and not always be packed in ‘‘the
same exclusive way’’ as the brand products. The pharma-
cists reported that more time-consuming work with the
patients was required for generic substitution and that
discussions regarding generics had taken over the patient–
pharmacist relationship. Nevertheless, the pharmacists
were positive about more generic prescribing.
In India, Basak and Sathyanarayana [35] carried out a
survey to evaluate community pharmacists’ and drug re-
tailers’ knowledge on and perceptions of generic drugs.
The study was conducted in 39 randomly selected private
pharmacies. Among the 66 respondents, 39 (59 %) were
drug retailers. Overall, 32 % did not know what generic
medicines were and 64 % believed that generic medicines
could be considered therapeutically equivalent with
branded drugs. However, 30 % believed that generics were
of inferior quality to the branded drugs. A higher level of
education had a significant correlation with knowledge of
generic medicines (P\ 0.01). Finally, the majority of the
respondents (80 %) were against generic substitution even
if the branded drug was not available.
4 Discussion
The present study shows that physicians and pharmacists
have acknowledged strategies for generic drug use as an
attempt to curtail increasing drug expenditure. However,
their perceptions vary according to the maturity of their
country’s healthcare systems (Table 3). The discussion
section below is divided thematically on the basis of the
topics discussed in the various articles.
4.1 The Manufacturer
It is well known that, in most countries, generic drugs can
be manufactured both nationally and internationally. A
key observation of the present review is the marked
variation in the level of trust health professionals had in
generic drug companies within countries. For instance, in
northern Europe, the health professionals felt confident
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about the generic drugs available in the market [17, 27,
34], and in Australia, the majority of pharmacists were
found to recommend generics [31]. However, it was
reported that physicians in southern Europe depended on
information provided by the brand drug manufacturers to
a greater degree than physicians in northern Europe [12,
13, 20]. In countries with less mature healthcare systems,
both physicians and pharmacists were highly concerned
about the manufacturing sources of generic drugs and the
companies’ trustworthiness [22, 24, 25, 29, 30, 32, 33]. In
some emerging healthcare systems, non-product-related
promotion was still much more accepted than the dis-
semination of product- or therapy-related information
[24].
Table 3 Summary of physicians’ and pharmacist’s perceptions of generic drugs as reported in the literature
Mature Healthcare Systems Less Mature Healthcare Systems
Awareness of generics Generics have entered the market because of growing healthcare costs and limited 
resources 
Generics can help to reduce costs for healthcare systems and/or patients
Benefits of generics Savings for state/insurer Access to drugs for people in need
Choice of generics by    
physicians and
pharmacists
Rely to a high degree on the generic 
manufacturers available in their 
own country
Rely only on the manufacturers they know 
of as trustworthy                                             
Awareness of drug 
control mechanisms
Trust the control routines for drugs 
in their own country
Of the opinion that the control routines for 
drugs vary in quality within their own 
country 
Bioequivalence (BE) Both physicians and pharmacists
understand BE to a certain degree
Pharmacists have the best 
understanding
Generally very low understanding of BE
BE not always required in the individual 
country
Pharmacists have slightly more knowledge
Value perception High value perception
In some countries, fear of losing 
patients through generic prescribing
Relatively low value perception 




Confusion and uncertainty regarding generic prescribing and substitution (for 
health professionals and patients)
Need for better information 
Additional workload for pharmacists due to high need for patient education and 
ensuring understanding
Exceptions Differentiation between various types of drugs (e.g.,
narrow therapeutic index, psychotropic drugs, chronic/acute)
Differentiation between patients
(elderly, polypharmacy patients, 
mentally ill, language problems, 
etc.)
Differentiation between patients’ 
affordability (wealth)
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4.2 Control Routines and Bioequivalence
Requirements
Inferior regulatory and control processes for drugs combined
with price pressures increase the risk of counterfeit drug
marketing. The present review found that both healthcare
personnel categories assessed appeared to have an under-
standing of the reliability of the control routines in their own
country and adapted their level of trust in the system
accordingly [12, 19, 23, 25–27, 34]. A general marked var-
iation between countries withmature healthcare systems and
thosewith developing healthcare systemswas observed once
again. It was further elucidated that, even if controls were in
place, the requirements for proof of bioequivalence were not
necessarily comprehensive [16, 19, 24, 25, 29, 35]. In gen-
eral, pharmacists appeared to have a better knowledge on the
concept of bioequivalence than physicians, particularly in
the case of elderly doctors, in whom the lack of familiarity
with the importance of bioequivalence for drug inter-
changeability was obvious [16, 22, 24, 25].
4.3 Therapeutic Window
Although articles related to specific drugs were not inclu-
ded in the present review, it was found that many physi-
cians and pharmacists differentiated between drugs when
considering generic substitution. They were convinced that
generic substitution should not occur for certain branded
drugs [17] and were especially sensitive to drugs with a
narrow therapeutic window [33].
4.4 Which Patients Should be Offered Generics?
In regions like the USA, Australia, and northern Europe,
generics were, in general, offered to patients from all
socioeconomic backgrounds [17, 27, 30, 31, 34]. However,
the physicians and pharmacists appeared to be worried about
certain patient categories for whom switching to generics or
switching between different generics should not be recom-
mended. Examples of patient categories in which confusion
may arise included elderly patients, polypharmacy users,
mentally ill patients, and patients who do not speak the local
language [15, 27, 30, 34]. In contrast, in some countries in
southern Europe and in some countries with an early-stage
healthcare system, both physicians and pharmacists raised
concerns regarding the loss of patients/customers if generics
were prescribed or suggested, as well as affordability for the
patient [14, 16, 21, 22, 28, 29].
4.5 The Quality of the Drug
In the present review, pharmacists from the Nordic countries
focused on the physical and packaging differences, such as
tablet coating and calendar packaging, between the branded
and generic drugs [34]. As mentioned above, health profes-
sionals in northern European countries had a high level of
confidence that a generic drug was identical to the branded
analogue regarding the active ingredient, dosage, and ther-
apeutic effects [17, 27, 34]. These health professionals
expressed a greater concern for patient adherence,whichmight
be lowered by misunderstanding and anxiety [15, 27]. In most
other countries, the two groups of health professionals were
more worried about the efficacy of the drug. In less mature
healthcare systems, generics were believed to have a lower or
uncertain efficacy andwere often looked uponas being inferior
in quality on the basis of negative experiences, attitudes, and
perceptions [12, 14–16, 18, 20–26, 29, 32, 33, 35].
4.6 More Information Needed
An overarching concern was the urgent need for more
reliable information on generic drugs and generic pre-
scribing/substitution [19, 22, 24–26, 31]. Some felt that this
should be included in medical or pharmaceutical training
curricula, since all practising physicians and pharmacists
were increasingly being confronted with the need to pre-
scribe or dispense these medications [22, 34]. The available
data indicated that pharmacists are currently better
informed, which is not surprising given that their frequent
contact with patients/customers requires an explanation of
the nature of generic drugs [15, 17, 28, 30, 31, 34].
5 Limitations
A limitation of the present study was the exclusion of
articles written in languages other than English.
6 Conclusions
The present study shows that physicians and pharmacists
are aware of the potential of generic drugs in the
improvement of global access to drugs. However, there are
marked differences in how pharmacists and physicians
consider the quality of generic drugs depending on the
maturity of the healthcare system in their own country.
This can be attributed to the fact that developed healthcare
systems have more reliable public control routines for
drugs in general as well as better bioequivalence require-
ments concerning generics in particular.
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